Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.

Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion-positive (-fp) solid tumours and ROS1-fp non-small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a non-invasive in vitro next-generation sequencing (NGS)-based diagnostic, detects genomic alterations in plasma circulating tumour DNA (ctDNA).

Use of cobalt blue light in grading cataract and estimating vision loss.

Purpose: To test an anecdotally reported cataract grading system predictive of a 20/50 visual threshold in cataract-induced vision loss using cobalt blue light.

Setting: Hennepin County Medical Center, Minneapolis, Minneapolis VA Medical Center, Minneapolis, and Regions Hospital, St. Paul, Minnesota, USA.

Erythropsia revisited.

We report a case of unilateral erythropsia lasting 1 week that occurred 18 years after cataract extraction and intraocular lens (IOL) implantation. The unaffected eye was pseudophakic and had an IOL with ultraviolet (UV) light protection; the affected eye had an IOL without UV light protection.

Identification and localization of major soluble vitreous proteins in human ocular tissue.

Purpose: To identify the major soluble proteins from human vitreous, and to establish a baseline for comparison of vitreous samples from eyes with various diseases.

Design: Laboratory investigation.

Methods: Normal vitreous was obtained from eight human donor eyes and from eight eyes of patients undergoing diabetic vitrectomy.